

Express Mail No.: EL 477 036 798 US

Attachment to Paper #7

LIST OF REFERENCES CITED BY APPLICANT (Use several sheets if necessary)				ATTY. DOCKET NO. 10271-047	APPLICATION NO. 09/996,288	
				APPLICANT Young et al.		
				FILING DATE November 28, 2001	GROUP 1641-1648	
U.S. PATENT DOCUMENTS						
EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS SUBCLASS	FILING DATE IF APPROPRIATE
88c	AA	4,526,938	7/2/85	Churchill et al.		
	AB	4,880,078	11/14/89	Inoue et al.		
	AC	5,128,326	7/7/92	Balazs et al.		
	AD	5,290,540	3/1/94	Prince et al.		
	AE	5,679,377	10/21/97	Bernstein et al.		
	AF	5,824,307	10/20/98	Johnson		
	AG	5,855,913	1/5/99	Hanes et al.		
	AH	5,874,064	2/23/99	Edwards et al.		
	AI	5,912,015	6/15/99	Bernstein et al.		
	AJ	5,916,597	6/29/99	Lee et al.		
	AK	5,934,272	8/10/99	Lloyd et al.		
	AL	5,985,309	11/16/99	Edwards et al.		
	AM	5,985,320	11/16/99	Edwards et al.		
	AN	5,989,463	11/23/99	Tracy et al.		
	AO	6,019,968	2/1/00	Platz et al.		
	AP	09/168,130		"Human-Murine Chimeric Antibodies Against Respiratory Syncytial Virus"		9/21/98
	AQ	09/866,490		"Epitope Based Vaccine for Respiratory Syncytial Virus F-Protein"		5/25/01
	AR	09/848,390		"Combination Therapy of Respiratory Diseases using Antibodies"		5/3/01
	AS	09/046,377		"Combination Therapy of Respiratory Diseases Using Antibodies and Anti-Inflammatory Agents"		5/3/01
	AT	09/797,760		"Methods of Enhancing Activity of Vaccines and Vaccine Compositions"		3/2/01
	AU	09/796,848		"High Potency Recombinant Antibodies and Methods for Producing Them"		3/1/01
	AV	09/781,052		"Antibody Gene Therapy with Adeno-Associated Viral Vectors"		2/8/01
	AW	09/771,415		"Ultra High Affinity Neutralizing Antibodies"		1/26/01
	AX	09/186,252		"High Potency Recombinant Antibodies and Methods for Producing Them"		3/1/00
	AY	09/168,426		"High Potency Recombinant Antibodies and Methods for Producing Them"		1/27/00
	AZ	5,811,524	0/22/98	Brams et al.		
	BA	5,840,298	11/24/98	Brams et al.		
	BB	5,866,125	2/2/99	Brams et al.		

AP-AY  
not  
in  
conformance  
88c  
5/7/2004

SBC	BC	5,955,364	9/21/99	Brams et al.			
↓	BD	5,958,765	9/28/99	Brams et al.			
↓	BE	2002 0001 798	1/3/02	Brams et al.			

## FOREIGN PATENT DOCUMENTS

		DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUBCLASS	TRANSLATION	
							YES	NO
SBC	BF	WO 91/05548	5/2/91	PCT				
	BG	WO 92/19244	11/12/92	PCT				
	BH	WO 96/20698	7/11/96	PCT				
	BI	WO 97/34631	9/25/97	PCT				
	BJ	WO 97/32572	9/12/97	PCT				
	BK	WO 97/44013	11/27/97	PCT				
	BL	WO 98/31346	7/23/98	PCT				
	BM	WO 99/15154	4/01/99	PCT				
	BN	WO 99/20253	4/29/99	PCT				
↓	BO	WO 99/66903	12/29/99	PCT				

## OTHER REFERENCES (Including Author, Title, Date, Pertinent Pages, Etc.)

SBC	BP	Abman et al., 1988, "Role of Respiratory Syncytial Virus in Early Hospitalizations for Respiratory Distress of Young Infants With Cystic Fibrosis", J Pediatr. 113(5):826-30.
	BQ	American Academy of Pediatrics Committee on Infectious Diseases: Use of Ribavirin in the Treatment of Respiratory Syncytial Virus Infection. Pediatrics. 1993 Sep;92(3):501-4.
	BR	Beeler et al., 1989, "Neutralization Epitopes of the F Glycoprotein of Respiratory Syncytial Virus: Effect of Mutation Upon Fusion Function", J Virol. 63(7):2941-50.
	BS	Bentley et al., 1980, "Human immunoglobulin variable region genes-- DNA Sequences of Two V Kappa Genes and a Pseudogene", Nature 288: 5194-5198
	BT	Cleek et al., 1997, "Biodegradable Polymeric Carriers for a bFGF Antibody for Cardiovascular Application" Pro. Int'l Symp. Control. Rel Bioact. Mater. 24: 853-854
	BU	Evans, A.S., 1989, Viral Infections of Humans, Epidemiology and Control, 3 <sup>rd</sup> ed., 525-44
	BV	Falsey et al., 1991, "Noninfluenza Respiratory Virus Infection in Long-Term Care Facilities", Infect Control Hosp Epidemiol. 12(10):602-8.
	BW	Feigen et al., 1987, Textbook of Pediatric Infectious Diseases, WB Saunders, Philadelphia, pp. 1653-1675
	BX	Garvie et al., 1980, "Outbreak of Respiratory Syncytial Virus Infection in the Elderly", Br Med J. 281(6250):1253-4.
	BY	Glezen et al., 1981, "Risk of Respiratory Syncytial Virus Infection for Infants From Low-Income Families in Relationship to Age, Sex, Ethnic Group, and Maternal Antibody Level", J Pediatr. 98(5):708-15.
	BZ	Groothuis et al., 1988, "Respiratory Syncytial Virus Infection in Children with Bronchopulmonary Dysplasia", Pediatrics. 82(2):199-203.
	CA	Groothuis et al., 1993, "Prophylactic Administration of Respiratory Syncytial Virus Immune Globulin to High-risk Infants and Young Children", The Respiratory Syncytial Virus Immune Globulin Study Group. N Engl J Med. 329(21):1524-30.
	CB	Hall et al., 1979, "Neonatal Respiratory Syncytial Virus Infection", N Engl J Med. 300(8):393-6.
	CC	Hall, C.B., 1993, Respiratory Syncytial: What We Know Now", Contemp. Pediatrics, 10: 92-110.
	CD	Hemming et al., 1985, "Studies of Passive Immunotherapy for Infections of Respiratory Syncytial Virus in the Respiratory Tract of a Primate Model", J Infect Dis. 152(5):1083-7.
↓	CE	Henderson et al., 1979, "Respiratory-Syncytial-Virus Infections, Reinfections and Immunity. A Prospective, Longitudinal Study in Young Children", N Engl J Med. 300(10):530-4.

SBC	CF	Hertz et al., 1989, "Respiratory Syncytial Virus-Induced Acute Lung Injury in Adult Patients With Bone Marrow Transplants: a Clinical Approach and Review of the Literature", <i>Medicine (Baltimore)</i> . 68(5):269-81.
	CG	Howard et al., 1989, "Intracerebral Drug Delivery in Rats with Lesion-Induced Memory Deficits", <i>J Neurosurg.</i> 71(1):105-12.
	CH	Johnson et al., 1987, "The G Glycoprotein of Human Respiratory Syncytial Viruses of Subgroups A and B: Extensive Sequence Divergence Between Antigenically Related Proteins", <i>Proc Natl Acad Sci U S A.</i> 84(16):5625-9.
	CI	Johnson et al., 1987, "Development of a Humanized Monoclonal Antibody (MEDI-493) With Potent <i>In Vitro</i> and <i>In Vivo</i> Activity Against Respiratory Syncytial Virus", <i>J Infect Dis.</i> 176(5):1215-24.
	CJ	Kapikian et al., 1969, "An Epidemiologic Study of Altered Clinical Reactivity to Respiratory Syncytial (RS) Virus Infection in Children Previously Vaccinated With an Inactivated RS Virus Vaccine", <i>Am J Epidemiol.</i> 89(4):405-21
	CK	Kim et al., 1969, "Respiratory Syncytial Virus Disease in Infants Despite Prior Administration of Antigenic Inactivated Vaccine", <i>Am J Epidemiol.</i> 89(4):422-34
	CL	Lam et al., 1997, "Microencapsulation of Recombinant Humanized Monoclonal Antibody for Local Delivery", <i>Proc. Int'l. Symp. Control Rel. Bioact. Mater.</i> 24:759-760
	CM	Lamprecht et al., 1976, "Role of Maternal Antibody in Pneumonia and Bronchiolitis Due to Respiratory Syncytial Virus", <i>J Infect Dis.</i> 134(3):211-7.
	CN	Levy et al., 1985, "Inhibition of Calcification of Bioprosthetic Heart Valves by Local Controlled-release Diphosphonate", <i>Science.</i> 228(4696):190-2.
	CO	MacDonald et al., 1982, "Respiratory Syncytial Viral Infection in Infants With Congenital Heart Disease", <i>N Engl J Med.</i> 307(7):397-400.
	CP	Morell et al., eds, 1986, <i>Clinical Use of Intravenous Immunoglobulins</i> , Academic Press, London, pp. 285-94.
	CQ	Murphy et al., 1991, "Effect of Passive Antibody on the Immune Response of Cotton Rats to Purified F and G HG Glycoproteins of Respiratory Syncytial Virus (RSV)", <i>Vaccine.</i> 9(3):185-9.
	CR	Murphy et al., 1988, "Passive Transfer of Respiratory Syncytial Virus (RSV) Antiserum Suppresses The Immune Response to the RSV Fusion (F) and Large (G) Glycoproteins Expressed By Recombinant Vaccinia Viruses", <i>J Virol.</i> 62(10):3907-10.
	CS	Murphy and Hall, 1994, "An Update on Approaches to the Development of Respiratory Syncytial Virus (RSV) and Parainfluenza Virus Type 3 (PIV3) Vaccines", <i>Virus Res.</i> 32(1):13-36.
	CT	Navas et al., 1992, "Improved Outcome of Respiratory Syncytial Virus Infection in a High-Risk Hospitalized Population of Canadian children. Pediatric Investigators Collaborative Network on Infections in Canada", <i>J Pediatr.</i> 121(3):348-54.
	CU	Ning et al., 1996, "Intratumoral Radioimmunotherapy of a Human Colon Cancer Xenograft Using a Sustained Release Gel", <i>Radiotherapy and Oncology</i> 39: 179-89
	CV	Ogra et al., 1988, "Respiratory Syncytial Virus Infection and the Immunocompromised Host", <i>Pediatr Infect Dis J.</i> 1988 Apr;7(4):246-9.
	CW	Palivizumab et al., 1998, "A Humanized Respiratory Syncytial Virus Monoclonal Antibody, Reduces Hospitalization From Respiratory Syncytial Virus Infection in High-Risk Infants", <i>The Impact-RSV Study Group. Pediatrics.</i> 102(3 Pt 1):531-7.
	CX	Pohl et al., 1992, "Respiratory Syncytial Virus Infections in Pediatric Liver Transplant Recipients", <i>J Infect Dis.</i> 165(1):166-9.
	CY	Press et al., 1970, "The Amino Acid Sequences of the Fd Fragments of Two Human Gamma-1 Heavy chains", <i>Biochem J.</i> 117(4):641-60
	CZ	Prince et al., 1985, "Immunoprophylaxis and Immunotherapy of Respiratory Syncytial Virus Infection in the Cotton rat", <i>Virus Res.</i> 3(3):193-206.
	DA	Prince et al., 1983, "Mechanisms of Immunity to Respiratory Syncytial Virus in Cotton Rats", <i>Infect Immun.</i> 42(1):81-7.
	DB	Prince et al., 1990, "Mechanism of Antibody-mediated Viral Clearance in Immunotherapy of Respiratory Syncytial Virus Infection of Cotton Rats", <i>J Virol.</i> 64(6):3091-2.
	DC	Prince et al., 1985, "Quantitative Aspects of Passive Immunity to Respiratory Syncytial Virus Infection in Infant Cotton Rats", <i>J Virol.</i> 55(3):517-20.
	DD	Ruuskanen et al., 1993, "Respiratory syncytial virus", <i>Curr Probl Pediatr.</i> 23(2):50-79.
✓	DE	Saez-Llorens et al., 1998, "Safety and Pharmacokinetics of an Intramuscular Humanized Monoclonal Antibody to Respiratory Syncytial Virus in Premature Infants and Infants with Bronchopulmonary Dysplasia", <i>Pediatric Infect Dis J.</i> 17:787-91

SBC	DF	Saudek et al., 1989, "A Preliminary Trial of the Pprogrammable Implantable Medication System for Insulin Delivery. N Engl J Med. 321(9):574-9.
	DG	Sefton, 1987, "Implantable Pumps". CRC Crit. Ref. Biomed. Eng. 14:20
	DH	Smith et al., 1991, "A Controlled Trial of Aerosolized Ribavirin in Infants Receiving Mechanical Ventilation for Severe Respiratory Syncytial Virus Infection". N Engl J Med. 325(1):24-9.
	DI	Song et al., 1995, "Antibody Mediated Lung Targeting of Long-Circulating Emulsions", PDA Journal of Pharmaceutical Science & Technology 50: 372-97
	DJ	Subramanian et al., "Safety, Tolerance and Pharmacokinetics of a Humanized Monoclonal Antibody to Respiratory Syncytial Virus in Premature Infants and Infants with Bronchopulmonary Dysplasia", Pediatric Infect Dis J. 17:110-115 (1998)
✓	DK	Walsh et al., 1987, "Immunization with Glycoprotein Subunits of Respiratory Syncytial Virus to Protect Cotton Rats Against Viral Infection". J Infect Dis. 155(6):1198-204.
EXAMINER <u>Stacy B. Chen</u> DATE CONSIDERED <u>July 11, 2003</u>		
*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.		



<b>LIST OF REFERENCES CITED BY APPLICANT</b> (Use several sheets if necessary)	ATTY DOCKET NO.	APPLICATION NO
	10271-047	09/996,288
	APPLICANT <b>Young et al.</b>	
	FILING DATE	GROUP
	November 28, 2001	1648

**U.S. PATENT DOCUMENTS**

*EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE
SBC	DL	5,939,068	8/17/99	Brams et al.			
	DU	6,537,809	3/25/03	Brams			
	DV	6,096,551	8/1/00	Barbas et al.			
	DW	5,693,762	12/2/97	Queen et al.			
	DX	5,585,089	12/17/96	Queen et al.			

**FOREIGN PATENT DOCUMENTS**

		DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUBCLASS	TRANSLATION	
							YES	NO
SBC	DY	WO 00/29584	5/25/00	PCT/us				
SBC	DM	WO 96/05229	2/22/96	us				

**OTHER REFERENCES (Including Author, Title, Date, Pertinent Pages, Etc.)**

SBC	DN	Hacking et al., 2002, "Respiratory syncytial virus - viral biology and the host response," J. Infection 45:18-24
	DO	Heard et al., 1999, "Two neutralizing human RSV antibodies: cloning, expression, and characterization," Mol. Med. 5:35-45
	DP	Landry et al., "Evaluation of reconstituted lophilized palivizumab given intravenously at 15 and 30 mg/kg," Poster Session, Tuesday, Infect. Dis. 166A: 969 (1999)
	DQ	Saez-Llorens et al., 1997, "Phase I/II open label multi dose escalation trial of a humanized respiratory syncytial virus (RSV) monoclonal antibody (Medi-493) administered intramuscularly (IM) in high risk children," Abstracts in Non HIV virology, ICAAC Toronto
	DR	Subramanian et al., 1997, "Randomized double blind placebo controlled dose escalation trial of a humanized respiratory syncytial virus monoclonal antibody in high risk infants," Poster session infect. dis. 130A:768
	DS	Sorbera et al., 1998, "Palivizumab," Drugs of the Future 23:970-976
	DT	Sorbera et al., 1998, "Palivizumab," Drugs Data Report 20:702-703
	DZ	Anderson et al., 1985, "Microneutralization test for respiratory syncytial virus based on an enzyme immunoassay," J. Clin. Microbiol. 22:1050-1052
	EA	Boulianne et al., 1984, "Production of functional chimaeric mouse/human antibody," Nature 312(5995):643-646
	EB	Carson et al., 1986, "Human lymphocyte hybridomas and monoclonal antibodies," Adv. Immunol. 38:275-311
	EC	Conrad et al., 1987, "Aerosolized ribavirin treatment of respiratory syncytial virus infection in infants hospitalized during an epidemic," Pediatr. Infect. Dis. J. 6(2):152-158
	ED	Cruse et al., 1995, Illustrated Dictionary of Immunology, Boca Raton: CRC Press, pp. 18-19
	EE	Dorland's Illustrated Medical Dictionary, 1994, 28 <sup>th</sup> ed., Philadelphia: WB Saunders p. 874
	EF	Duenas et al., 1996, "In vitro immunization of naive human B cells yields high affinity immunoglobulin G antibodies as illustrated by phage display," Blackwell Science Limited, pp. 1-7
	EG	Duenas et al., 1996, "Selection of phage displayed antibodies based on kinetic constants," 33(3):279-285
	EH	Everitt et al., 1996, "The pharmacokinetics, antigenicity, and fusion-inhibition activity of RSHZ19, a humanized monoclonal antibody to respiratory syncytial virus, in healthy volunteers," J. Infect. Dis.
	EI	Foote et al., 1995, "Kinetic and affinity limits on antibodies produced during immune response," Proc. Nat'l Acad. Science USA 92:1254-1256
	EJ	Foote et al., 1991, "Kinetic maturation of an immune response," Nature vol. 352

<i>SBC</i>	EK	Glaser et al., 1992, "Antibody engineering by codon-based mutagenesis in a filamentous phage vector system," J. Immunol. 149:3903-3913
	EL	Greenspan et al., 1999, Nature Biotechnology 7:936-937
	EM	Groves et al., 1987, "Production of an ovine monoclonal antibody to testosterone by an interspecies fusion," Hybridoma 6(1):71-76
	EN	Hall et al., 1985, "Ribavirin treatment of respiratory syncytial viral infection in infants with underlying cardiopulmonary disease," JAMA 254(21):3047-3051
	EO	Hall et al., 1983, "Aerosolized ribavirin treatment of infants with respiratory syncytial viral infection. A randomized double-blind study," N. Engl. J. Med. 308(24):1443-1447
	EP	Hall et al., 1975, "Nosocomial respiratory syncytial virus infections," N. Engl. J. Med. 293(26):1343-1346
	EQ	Haynes et al., 2002, "Neutralizing anti-F glycoprotein and anti-substance P antibody treatment effectively reduces infection and inflammation associated with respiratory syncytial virus infection," J. Virol. 76(14):6873-6881
	ER	Johnson et al., 1999, "A direct comparison of the activities of two humanized respiratory syncytial virus monoclonal antibodies: MEDI-493 and RSHZ19," J. Infect. Dis. 180(1):35-40
	ES	Karlsson et al., 1997, "Experimental design for kinetic analysis of protein-protein interactions with surface plasmon resonance biosensors," J Immunol. Meth.
	ET	Knapik et al., 2000, "Fully synthetic human combinatorial antibody libraries (HuCAL) based on modular consensus frameworks and CDRs randomized with trinucleotides," Academic Press, pp. 57-86
	EU	Liu et al., 1987, "Expression of mouse:human immunoglobulin heavy-chain cDNA in lymphoid cells," Gene 54(1):33-40
	EV	LoBuglio et al., 1989, "Mouse/human chimeric monoclonal antibody in man: kinetics and immune response," Proc. Natl. Acad. Sci. USA 86(11):4220-4224
	EW	Morrison et al., 1985, "Transfectomas provide novel chimeric antibodies," Science 229(4719):1202-1207
	EX	Morrison et al., 1984, "Chimeric human antibody molecules: mouse antigen-binding domains with human constant region domains," Proc. Natl. Acad. Sci. USA 81(21):6851-6855
	EY	Myszka et al., 1999, "Survey of the 1998 optical biosensor literature," J. Mol. Recog.
	EZ	Newman et al., 1992, "'Primitization' of recombinant antibodies for immunotherapy of human diseases: A Macaque/Human chimeric antibody against human CD4," 10:1455-1460
	FA	Prince et al., 1996, "Treatment of parainfluenza virus type 3 bronchiolitis and pneumonia in a cotton rat model using topical antibody and glucocorticosteroid," J. Infect. Dis. pp.598-608
	FB	Raman et al., 1992, "Diffusion-limited rates for monoclonal antibody binding to cytochrome," Biochem.
	FC	Roost et al., 1995, "Early high-affinity neutralizing anti-viral IgG responses without further overall improvements of affinity," PNAS USA 92:1257-1261
	FD	Rosok et al., 1995, "A combinatorial library strategy for the rapid humanization of anticarcinoma BR 96 Fab," JBC 271(27):22611-22618
	FE	Rudikoff et al., 1982, "Single amino acid substitution altering antigen-binding specificity," Proc. Natl. Acad. Sci. USA 79(6):1979-1983
	FF	Sahagan et al., 1986, "A genetically engineered murine/human chimeric antibody retains specificity for human tumor-associated antigen," J. Immunol. 137(3):1066-1074
	FG	Schier et al., 1996, "Isolation of picomolar affinity anti-c-erbB-2 single-chain Fv by molecular evolution of the complementarity determining regions in the center of the antibody binding site," J. Mol. Biol. 263(4):551-567
	FH	Steplewski et al., 1988, "Biological activity of human-mouse IgG1, IgG2, IgG3, and IgG4 chimeric monoclonal antibodies with antitumor specificity," Proc. Natl. Acad. Sci. USA 85(13):4852-4856
	FI	Sun et al., 1987, "Chimeric antibody with human constant regions and mouse variable regions directed against carcinoma-associated antigen 17-1A," Proc. Natl. Acad. Sci. USA 84(1):214-218
	FJ	Takeda et al., 1985, "Construction of chimeric processed immunoglobulin genes containing mouse variable and human constant region sequences," Nature 314(6010):452-454
	FK	Talwar et al., 1976, "Isoimmunization against human chorionic gonadotropin with conjugates of processed beta-subunit of the hormone and tetanus toxoid," Proc. Natl. Acad. Sci. USA 73(1):218-222
	FL	van Wyke et al., 1985, "Antigenic variation in the hemagglutinin-neuraminidase protein of human parainfluenza type 3 virus," Virology 143(2):569-582
	FM	Wald et al., 1988, "In re ribavirin: a case of premature adjudication?" J. Pediatr. 112(1):154-158
	FN	Wright et al., 1982, "Administration of a highly attenuated, live respiratory syncytial virus vaccine to adults and children," Infect. Immun. 37(1):397-400
	FO	Wu et al., 1998, "Stepwise in vitro affinity maturation of Vitaxin, an avb-specific humanized mAb," PNAS 95:6037-6042
✓	FP	Geneseq Database, Accession no: AAW70933, entry date Oct. 1998 from patent no FR2758331-A1 of Bourgeois et al.

EXAMINER *Stacy B. Chen*DATE CONSIDERED *May 7, 2004*

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

# LIST OF REFERENCES CITED BY APPLICANT (Use several sheets if necessary)

ATTY DOCKET NO.

10271-047

APPLICATION NO

09/996,288

APPLICANT

Young et al.

FILING DATE

November 28, 2001

GROUP

1648

## U.S. PATENT DOCUMENTS

*EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE
<i>SBC</i>	DL	5,939,068	8/17/99	Brams et al.			

## FOREIGN PATENT DOCUMENTS

		DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUBCLASS	TRANSLATION	
							YES	NO
SBC	DM	WO 96/05229	2/22/96	PCT				

## OTHER REFERENCES (Including Author, Title, Date, Pertinent Pages, Etc.)

<i>SBC</i>	DN	Hacking et al., 2002, "Respiratory syncytial virus - viral biology and the host response," J. Infection 45:18-24
	DO	Heard et al., 1999, "Two neutralizing human RSV antibodies: cloning, expression, and characterization," Mol. Med. 5:35-45
	DP	Landry et al., "Evaluation of reconstituted lophilized palivizumab given intravenously at 15 and 30 mg/kg," Poster Session, Tuesday, Infect. Dis. 166A: 969
	DQ	Saez-Llorens et al., 1997, "Phase I/II open label multi dose escalation trial of a humanized respiratory syncytial virus (RSV) monoclonal antibody (Medi-493) administered intramuscularly (IM) in high risk children," Abstracts in Non HIV virology, ICAAC Toronto
	DR	Subramanian et al., 1997, "Randomized double blind placebo controlled dose escalation trial of a humanized respiratory syncytial virus monoclonal antibody in high risk infants," Poster session infect. dis. 130A:768
	DS	Sorbera et al., 1998, "Palivizumab," Drugs of the Future 23:970-976
↓	DT	Sorbera et al., 1998, "Palivizumab," Drugs Data Report 20:702-703

EXAMINER

*Stacy B. Cher*

DATE CONSIDERED

*May 7, 2004*

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.